TD Cowen analyst Joseph Thome lowered the firm’s price target on PTC Therapeutics (PTCT) to $50 from $56 and keeps a Hold rating on the shares after the FDA issued a complete response letter for vatiquinone in Friedreich’s ataxia. The firm removed Friedreich’s ataxia from its model and believes a a second successful Phase III study will likely be required for approval.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics Receives FDA Complete Response Letter
- PTC Therapeutics receives Complete Response Letter for vatiquinone NDA
- PTC Therapeutics’ Earnings Call Highlights Sephience Success
- PTC Therapeutics price target lowered to $70 from $72 at Baird
- PTC Therapeutics price target raised to $56 from $52 at TD Cowen